Promising to redefine the landscape with its latest solutions, the company hopes to take center stage, offering advancements in data management and patient engagement. Join us for an exclusive preview of how Qinesca is poised to win over the industry and why this unveiling is the must-see event of the conference.
Product and Service Innovations: Can you share any new products or services your company is unveiling at this year’s DIA?
As a trusted global partner bringing together best-in-class technology and scientific expertise, Qinecsa connect life science companies, public health, regulatory sectors, and the biotech and pharma landscape, including large pharma, to the right solutions. Due to our innovative culture, providing comprehensive end-to-end drug safety management and compliance, we are always looking to expand our technology offerings. To further this commitment to innovation, Qinecsa recently acquired Insife ApS (Insife), a well-established software, technology, and consultancy firm specializing in developing revolutionary pharmacovigilance platforms. This acquisition allows us to leverage Insife’s expertise in software development and consultancy to enhance our existing pharmacovigilance services and accelerate further innovation in the field. Acquiring Insife, the expertise of their team and its additional proven pharmacovigilance platforms has enhanced the capability of Qinecsa’s already existing technology to help transform the role of pharmacovigilance, provide faster and more innovative solutions for our clients, and most importantly, continue to improve patient safety.
How do your latest innovations address current challenges in the pharmaceutical and healthcare industries?
The acquisition of Insife enables Qinecsa to leverage expertise in software development and consultancy, enhancing existing pharmacovigilance (PV) services and accelerating further innovation. This includes the HALOPV platform which manages all multivigilance processes, from operational to scientific, in the world’s first fully comprehensive and cohesive solution. Traditionally, global drug safety is constructed around a safety database and additional tools are integrated to secure affiliate and partner reporting, compliance management, literature monitoring, regulatory intelligence and risk management. However, HALOPV can handle it all.
Market Trends and Challenges: What major trends do you see shaping the future of the pharmaceutical industry?
Higher volumes of data and greater trial complexity are forcing the pharmaceutical industry to adopt new ways of working and PV is no different. We are moving from being a necessary, safety and cost-saving function to a proactive, value-creation function.
Automation and artificial intelligence (AI) are changing the way we work, offering new opportunities to streamline processes. We see the adoption of these technologies as a ladder with manual processes at the bottom, basic process automation as the first rung and so on until you get to AI which increases process efficiency and removes human error at the top.
What are the biggest challenges your company is currently facing, and how are you addressing them?
The PV sector has several historic challenges including outdated, costly and labor-intensive processes, parallel safety organizations creating greater complexity and inconsistent reporting structures. Several of these challenges are already being overcome at Qinecsa by leveraging new technologies to create more streamlined processes. There are also opportunities to consolidate a dispersed geographical footprint through virtual working and to centralize reporting structures through platform approaches.
However, simply introducing new technologies is not enough, we need to ensure they are supported by the right culture and processes. This relies on credible, up-to-date messaging, strong leadership based on data-driven decisions, consistent measurement of progress and a continuous cycle of improvement.
Technology and Digital Transformation: How is your company incorporating digital transformation into its business model?
Qinecsa has several industry-leading technologies which support the PV landscape. Our Reportum Platform is a unified adverse event platform managing both digital and analogue reports across global sources and languages. It offers a digital-first experience for consumers, healthcare professionals and expert pharma users. Our Commonwealth Vigilance Workbench (CVW) signal detection platform ensures all potential signals are tracked with clear prioritization. Robust data integration and functionality enables analysis of aggregate data from multiple adverse event datasets, supported by configurable planning and workflow capabilities.
